Repurposing auranofin, ebselen, and PX-12 as antimicrobial agents targeting the thioredoxin system

Holly C. May, Jieh Juen Yu, M. N. Guentzel, James P. Chambers, Andrew P. Cap, Bernard P. Arulanandam

Research output: Contribution to journalShort surveypeer-review

23 Scopus citations

Abstract

As microbial resistance to drugs continues to rise at an alarming rate, finding new ways to combat pathogens is an issue of utmost importance. Development of novel and specific antimicrobial drugs is a time-consuming and expensive process. However, the re-purposing of previously tested and/or approved drugs could be a feasible way to circumvent this long and costly process. In this review, we evaluate the U.S. Food and Drug Administration tested drugs auranofin, ebselen, and PX-12 as antimicrobial agents targeting the thioredoxin system. These drugs have been shown to act on bacterial, fungal, protozoan, and helminth pathogens without significant toxicity to the host. We propose that the thioredoxin system could serve as a useful therapeutic target with broad spectrum antimicrobial activity.

Original languageEnglish (US)
Article number336
JournalFrontiers in Microbiology
Volume9
Issue numberMAR
DOIs
StatePublished - Mar 5 2018
Externally publishedYes

Keywords

  • Antimicrobial
  • Antimicrobial resistance
  • Drug target
  • Flavoenzyme
  • Thioredoxin

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Repurposing auranofin, ebselen, and PX-12 as antimicrobial agents targeting the thioredoxin system'. Together they form a unique fingerprint.

Cite this